Bayer AG NA Stock Timeline

TickerBAYN.XETRA
Current Price –
Bayer AG NA – stock chart

Five-year timeline for Bayer AG NA (BAYN.XETRA): major events, developments and context behind the stock's recent history.

View full stock analysis →

5-year stock timeline

2026-02-17 — Proposed U.S. nationwide Roundup class settlement; litigation provisions increased

Monsanto (Bayer) announced a proposed nationwide class settlement to resolve current and future Roundup™ (glyphosate) claims through a long-term claims program. Monsanto will make declining capped annual payments for up to 21 years totaling up to $7.25 billion. Bayer said the resolutions and related costs would increase its provisions and litigation liabilities and shifted its 2025 results announcement to reflect the settlement accounting [9].

Market and investor reaction framed this as an effort to put long-running glyphosate litigation largely behind the company and to replace episodic large jury verdicts with a predictable long-dated payment stream. The move was presented as de-risking the balance sheet and enabling management to refocus on operations and capital allocation, though investors noted near-term cash flow and funding pressures from the payouts and bond maturities.

Bayer stated that provisions and liabilities for litigation would rise from €7.8 billion (including €6.5 billion for glyphosate) as of 30 September 2025 to €11.8 billion (including €9.6 billion for glyphosate). Estimated litigation-related payouts in 2026 could be about €5.0 billion. The company also disclosed an $8 billion bank loan facility to secure immediate financing and said ultimate financing would use senior bonds and equity-credit instruments [9].

2025 — Continued litigation outcomes, balance-sheet focus and guidance timing

During 2025 Bayer continued to resolve individual Roundup and PCB cases while preparing its year-end financials and updated guidance. Litigation provision builds and settlements remained a central corporate issue driving disclosure and timing of results [9].

Investors saw 2025 as the year when litigation cashflows and provisions dominated capital allocation and near-term free cash flow, but also as the period when management aimed to close legacy litigation risk so the market could re-rate Bayer on operating performance in Pharma, Crop Science and Consumer Health.

Bayer reported litigation provisions (carryover from 30 September 2025 figures) in the €7.8 billion range prior to the 2026 settlement announcement, of which €6.5 billion related to glyphosate [9].

2024 — Supervisory Board and governance steps; preparatory board-level changes after investor pressure

Bayer's Supervisory Board and governance disclosures reflected the completed CEO succession planning and emphasized strategic review outcomes presented at the 2024 Annual Stockholders' Meeting and related supervisory board communications [4][11].

After years of investor pressure over strategy and returns following the Monsanto acquisition, governance messaging in 2024 emphasized leadership renewal, strategic review and an intent to improve capital discipline and operational execution. This shifted investor perception from litigation-dominated headline risk toward a turnaround and reshaping narrative under new leadership.

Public filings and supervisory-board material documented the appointment timetable (Bill Anderson appointed to Board of Management effective 1 April 2023; CEO since 1 June 2023) and referenced the 2023 sales level of approximately €50.7 billion (currency- and portfolio-adjusted sales increase approximately 9%) as background for strategic evaluation [4][15].

2023 — CEO change: Bill Anderson named CEO; Werner Baumann retirement

Bayer announced an external CEO hire. Bill Anderson (ex-Roche Pharmaceuticals executive) was appointed to the Board of Management effective 1 April 2023 and became CEO on 1 June 2023. Werner Baumann, who led the Monsanto acquisition, retired at end of May 2023 [6][11].

The appointment of an outsider with a strong pharma background signaled to markets a break with the prior era and investor impatience with returns. Investors interpreted the move as a potential catalyst for operational refocus, possible portfolio moves, and governance reform to restore credibility after years of litigation and underperformance — shifting perception toward a possible turnaround if execution and litigation resolution progressed.

Bayer reported currency- and portfolio-adjusted sales of about €50.7 billion for the prior reporting period and governance disclosures documented the succession timeline [15][11].

2021 — Legacy litigation and Monsanto acquisition aftermath; earnings and reputation impact

Bayer spent 2021 continuing to address the fallout from Monsanto's Roundup litigation (large numbers of plaintiff cases, jury verdicts, and settlement negotiations) and managing the financial and reputational consequences of the Monsanto acquisition completed in 2018.

Through 2021 investors viewed Bayer as still heavily affected by legacy litigation risk and headline legal outcomes, which impaired the company's growth narrative and contributed to a perception of constrained upside and a value/turnaround trade rather than a safe compounder. Pressure mounted for governance change and clearer plans to resolve liabilities.

Public reporting in the period documented substantial litigation exposures and settlement negotiations (leading to later large settlement programs), and the company's multi-billion euro provisions and settlement discussions in subsequent years traceable to the litigation originating before and during 2021 [5][9].

Get More Stock Analyses Like This

Receive hand-picked stock recommendations with detailed analyses every week

Start Free Trial
© Leeway
PWP Leeway UG (haftungsbeschränkt)
Leeway Icon